Parthenolide

• CAT Number: I002583
• CAS Number: 20554-84-1
• Molecular Formula: C₁₅H₂₀O₃
• Molecular Weight: 248.32
• Purity: ≥95%
• Target: HDAC
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• InChI: InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
• InChIKey: KTEXNACQROZXEV-PVLRGYAZSA-N
• SMILES: CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C

Parthenolide (PTL) is a sesquiterpene lactone which can induce apoptosis in cancer cells and eradicate cancer stem cells. Parthenolide can deplete HDAC1 protein without affecting other class I/II HDACs.IC50 value:Target: HDAC1; Apoptosis inducer; NF-kBin vitro: Parthenolide (PTL) induces apoptosis and cell cycle arrest in human lung cancer cells. Moreover, PTL treatment in NSCLC cells increases expression of TNFRSF10B/DR5 and PMAIP1/NOXA [1]. parthenolide dose-dependently inhibited RANKL-mediated osteoclast differentiation in BMMs without any evidence of cytotoxicity and the phosphorylation of p38, ERK, and IκB as well as IκB degradation by RANKL treatment. Parthenolide suppressed the expression of NFATc1, OSCAR, TRAP, DC-STAMP, and cathepsin K in RANKL-treated BMMs. Furthermore, parthenolide down regulated the stability of c-Fos protein, but could not suppress the expression of c-Fos [2]. the sesquiterpene lactone parthenolide (PN), which specifically depletes HDAC1 protein without affecting other class I/II HDACs. HDAC1 depletion occurred through proteasomal degradation and resulted in transcriptional consequences comparable to those observed with pan-HDACi [5].in vivo: The effects of parthenolide (PTN), a nuclear factor-kappa B inhibitor and sesquiterpene lactone, on polyethylene particle-induced osteolysis in vivo were investigated using a mouse calvarial model [3].dimethylamino-parthenolide (DMAPT), a water soluble parthenolide analog, intranasal instillation of low doses of DMAPT significantly reduced the overall lung tumor multiplicity by 39%. Interestingly, the drug was specifically effective (62% reduction) against bigger lung tumors (> 2 mm), which have a higher potential to develop into lung adenocarcinoma in mice [4].

Reference

1:Parthenolide promotes apoptotic cell death and inhibits the migration and invasion of SW620 cells. Liu YC, Kim SL, Park YR, Lee ST, Kim SW.Intest Res. 2017 Apr;15(2):174-181. doi: 10.5217/ir.2017.15.2.174. Epub 2017 Apr 27. PMID: 28522946 2:Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, Zhang J.Oncotarget. 2017 Apr 4;8(14):23436-23447. doi: 10.18632/oncotarget.15584. PMID: 28423582 Free PMC Article3:Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Morel KL, Ormsby RJ, Bezak E, Sweeney CJ, Sykes PJ.Radiat Res. 2017 May;187(5):501-512. doi: 10.1667/RR14710.1. Epub 2017 Mar 3. PMID: 28398879 4:Parthenolide reduces gene transcription of prosurvival mediators in U937 cells. Mohammadi S, Zahedpanah M, Nikbakht M, Shaiegan M, Hamidollah G, Nikugoftar M, Rahmani B, Hamedi Asl D.Exp Oncol. 2017 Mar;39(1):30-35. PMID: 28361855 5:Parthenolide attenuates cerebral ischemia/reperfusion injury via Akt/GSK-3β pathway in PC12 cells. Zhang JF, Zhang L, Shi LL, Zhao ZH, Xu H, Liang F, Li HB, Zhao Y, Xu X, Yang K, Tian YF.Biomed Pharmacother. 2017 May;89:1159-1165. doi: 10.1016/j.biopha.2017.03.009. Epub 2017 Mar 24. PMID: 28314243 6:Parthenolide inhibits the initiation of experimental autoimmune neuritis. Zhang M, Liu RT, Zhang P, Zhang N, Yang CL, Yue LT, Li XL, Liu Y, Li H, Du J, Duan RS.J Neuroimmunol. 2017 Apr 15;305:154-161. doi: 10.1016/j.jneuroim.2017.02.003. Epub 2017 Feb 8. PMID: 28284336 7:Synthesis of dual-action parthenolide prodrugs as potent anticancer agents. Taleghani A, Nasseri MA, Iranshahi M.Bioorg Chem. 2017 Apr;71:128-134. doi: 10.1016/j.bioorg.2017.01.020. Epub 2017 Feb 1. PMID: 28215600 8:Parthenolide suppresses pancreatic cell growth by autophagy-mediated apoptosis. Liu W, Wang X, Sun J, Yang Y, Li W, Song J.Onco Targets Ther. 2017 Jan 23;10:453-461. doi: 10.2147/OTT.S117250. eCollection 2017. PMID: 28176967 Free PMC Article9:Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation. Kim SL, Kim SH, Park YR, Liu YC, Kim EM, Jeong HJ, Kim YN, Seo SY, Kim IH, Lee SO, Lee ST, Kim SW.Mol Cancer Res. 2017 Feb;15(2):141-151. doi: 10.1158/1541-7786.MCR-16-0101. Epub 2016 Nov 14. PMID: 28108625 10:Synthesis and anti-acute myeloid leukemia activity of C-14 modified parthenolide derivatives. Yang Z, Kuang B, Kang N, Ding Y, Ge W, Lian L, Gao Y, Wei Y, Chen Y, Zhang Q.Eur J Med Chem. 2017 Feb 15;127:296-304. doi: 10.1016/j.ejmech.2016.12.044. Epub 2016 Dec 23. PMID: 28068601